Repair of the anterior cruciate ligament has recently regained interest over the past decade. Such repairs can be augmented with nonabsorbable suture for strength or biologic scaffolds to promote healing. This technique uses the BioBrace, a porous 3‐dimensional collagen scaffold made from bioresorbable bovine type I collagen that is reinforced with poly(L‐lactic acid) microfilaments. The scaffold provides mechanical load‐sharing properties and can increase biologic healing potential. This technique describes an anterior cruciate ligament repair with BioBrace augmentation.
Graft options for posterior cruciate ligament reconstruction include both autografts and allografts, with hamstring autografts and Achilles tendon allografts being the most common options. Although not as utilized, quadriceps tendon allografts have advantages similar to those that have driven the use of quadriceps autografts in knee reconstruction, such as favorable biomechanical properties and increased cross‐sectional area. This article describes the use of quadriceps tendon allograft with bone block and without bone block for posterior cruciate ligament reconstruction. Surgical techniques, fixation methods, and clinical indications of each graft are discussed, as well as the pearls and pitfalls of each technique.
Background: Non-union is a challenging complication following long bone fractures. Demineralized bone matrix (DBM) has been increasingly utilized, however, its role in managing long bone non-union remains unclear. This systematic review evaluates the published research on the effectiveness of DBM in treating long bone non-union. Sources of data: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, PubMed, Embase, and Scopus were searched from inception to March 2026 for studies assessing DBM use in adult long bone non-union. Areas of agreement: Eight studies including 340 patients were included. DBM was used alone or combined with autologous bone marrow concentrate (BMC), platelet-rich fibrin (PRF), platelet-rich plasma (PRP), or cancellous allograft chips. Union rates were similar when comparing DBM and iliac crest bone grafting (ICBG). DBM-treated patients achieved 79%–100% union (mean time to union between 3.7 and 11.9 months) versus 80%–100% for ICBG. Complications were minimally reported with no DBM-specific adverse events. Areas of controversy: Significant heterogeneity existed in DBM formulation, volume, and administration strategies. Studies utilized putty, strips, and injectable formulations, with volumes ranging 1–10 cc. DBM was also variably combined with PRP, BMC, or cancellous allograft chips. Outcome reporting was not standardized. Growing points: DBM appears to be an effective grafting strategy across diverse clinical applications and may offer a viable alternative to autologous grafting. Areas timely for developing research: Further high-quality randomized controlled trials with consistent outcome measures are needed to define optimal use of DBM in treating long bone non-union.